Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > GlaxoSmithKline > December 29, 2010

      GSK Bets on Outcome of Kidney Cancer Trial


      GlaxoSmithKline is literally putting money on the outcome of a clinical trial now in progress, pitting its pazopanib (Votrient) for advanced renal cell carcinoma against sunitinib (Sutent).

      In an effort to persuade the U.K.'s National Health Service to pay for pazopanib, which GSK has priced somewhat higher than sunitinib, the company has promised to rebate some of the NHS' expenditures for the drug if the ongoing trial shows that pazopanib is inferior to its rival.

      The rebate would be in addition to a 12.5% discount off pazopanib's list price, which eliminates its premium over sunitinib.

      Britain's National Institute for Health and Clinical Excellence (NICE), which provides guidances on medical technologies that the NHS nearly always follows, has recommended that the service accept the deal.

      The study, called COMPARZ, began in 2008 and is expected to close data collection next May. Final results are expected in mid-2012.

      Nearly 900 patients with locally advanced or metastatic renal cell carcinoma have been enrolled. The prespecified primary outcome is progression-free survival, with secondary measures that include overall survival, objective response rate, duration of response, and safety.

      On the basis of existing studies, NICE determined that pazopanib would not be cost-effective unless GSK agreed to match sunitinib's retail price and provide the rebate if pazopanib turns out to be inferior in the head-to-head study.

      Both drugs are oral inhibitors of tyrosine kinases associated with growth factors that promote tumor expansion. Sunitinib targets the vascular endothelial growth factor (VEGF) kinase, whereas pazopanib inhibits kinases for both VEGF and platelet-derived growth factor.

      Studies have suggested that pazopanib has a better side effect profile, but the two drugs have not been compared directly before in a randomized trial.

      NICE's guidance on the GSK deal did not specify the amount of the rebate that the company would pay if COMPARZ fails to demonstrate equality or superiority for pazopanib. It was among details provided to the agency "commercially in confidence," the guidance document said.

      Dec 29, 2010


      Share this Article!

    Back to top^